Abstract
We agree with Drs Lozano, Garcia, and Barriales that dual antiplatelet therapy should be recommended for 12 months after drug-eluting stent (DES) placement. We also agree with ACC/AHA PCI guidelines that included a provision of 12 months of clopidogrel therapy for patients not at high risk of bleeding.1 As shown in our report, the lower risk of ischemic complications on dual antiplatelet therapy (DAPT) must be balanced with the increased bleeding risk.2 Accordingly, a multidimensional approach is needed to address the risks and benefits of DAPT that takes into account the following: (1) appropriate patient selection to maximize the benefit while …
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
